Morgan Stanley’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-67,118
| Closed | -$329K | – | 8390 |
|
|
2021
Q3 | $329K | Sell |
67,118
-6,115
| -8% | -$29.7K | ﹤0.01% | 5733 |
|
|
2021
Q2 | $387K | Sell |
73,233
-265,481
| -78% | -$1.37M | ﹤0.01% | 5685 |
|
|
2021
Q1 | $1.63M | Sell |
338,714
-768,511
| -69% | -$4.01M | ﹤0.01% | 4419 |
|
|
2020
Q4 | $4.79M | Buy |
1,107,225
+807,951
| +270% | +$3.46M | ﹤0.01% | 3300 |
|
|
2020
Q3 | $1.23M | Sell |
299,274
-48,876
| -14% | -$189K | ﹤0.01% | 4059 |
|
|
2020
Q2 | $892K | Sell |
348,150
-166,947
| -32% | -$491K | ﹤0.01% | 4258 |
|
|
2020
Q1 | $1.49M | Buy |
515,097
+482,376
| +1,474% | +$2.16M | ﹤0.01% | 3622 |
|
|
2019
Q4 | $124K | Buy |
32,721
+19,040
| +139% | +$91.1K | ﹤0.01% | 5582 |
|
|
2019
Q3 | $70K | Buy |
13,681
+12,182
| +813% | +$75.2K | ﹤0.01% | 5577 |
|
|
2019
Q2 | $10K | Sell |
1,499
-6,598
| -81% | -$38K | ﹤0.01% | 6146 |
|
|
2019
Q1 | $58K | Sell |
8,097
-546,172
| -99% | -$4.91M | ﹤0.01% | 5609 |
|
|
2018
Q4 | $4.73M | Buy |
554,269
+506,081
| +1,050% | +$6.58M | ﹤0.01% | 2974 |
|
|
2018
Q3 | $965K | Sell |
48,188
-23,097
| -32% | -$542K | ﹤0.01% | 4569 |
|
|
2018
Q2 | $1.84M | Buy |
71,285
+5,045
| +8% | +$140K | ﹤0.01% | 4151 |
|
|
2018
Q1 | $1.58M | Sell |
66,240
-137,776
| -68% | -$4.34M | ﹤0.01% | 4210 |
|
|
2017
Q4 | $6.92M | Buy |
204,016
+173,230
| +563% | +$4.84M | ﹤0.01% | 2741 |
|
|
2017
Q3 | $652K | Buy |
30,786
+3,746
| +14% | +$68.7K | ﹤0.01% | 4711 |
|
|
2017
Q2 | $472K | Sell |
27,040
-3,308
| -11% | -$54.7K | ﹤0.01% | 4837 |
|
|
2017
Q1 | $531K | Sell |
30,348
-25,580
| -46% | -$436K | ﹤0.01% | 4798 |
|
|
2016
Q4 | $944K | Buy |
55,928
+44,398
| +385% | +$687K | ﹤0.01% | 4509 |
|
|
2016
Q3 | $189K | Buy |
11,530
+9,789
| +562% | +$149K | ﹤0.01% | 5046 |
|
|
2016
Q2 | $26K | Sell |
1,741
-4,159
| -70% | -$68.6K | ﹤0.01% | 5765 |
|
|
2016
Q1 | $85K | Sell |
5,900
-2,407
| -29% | -$40.5K | ﹤0.01% | 5387 |
|
|
2015
Q4 | $235K | Sell |
8,307
-190
| -2% | -$3.2K | ﹤0.01% | 5000 |
|
|
2015
Q3 | $142K | Sell |
8,497
-3,474
| -29% | -$79K | ﹤0.01% | 5256 |
|
|
2015
Q2 | $314K | Sell |
11,971
-3,007
| -20% | -$58.5K | ﹤0.01% | 4993 |
|
|
2015
Q1 | $262K | Sell |
14,978
-10,647
| -42% | -$182K | ﹤0.01% | 5063 |
|
|
2014
Q4 | $445K | Buy |
25,625
+25,224
| +6,290% | +$383K | ﹤0.01% | 4745 |
|
|
2014
Q3 | $7K | Sell |
401
-10,110
| -96% | -$174K | ﹤0.01% | 6277 |
|
|
2014
Q2 | $192K | Buy |
+10,511
| New | +$188K | ﹤0.01% | 5179 |
|
Morgan Stanley's ADMS Position: Q4 2021 in Review
Morgan Stanley sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 67,118 shares — an estimated $329K sold.
Morgan Stanley first reported a position in ADMS in Q2 2014 and held it in 30 quarters. The position peaked at $6.92M in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Morgan Stanley reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Morgan Stanley sold 67,118 Adamas Pharmaceuticals shares in Q4 2021, an estimated $329K.
- Morgan Stanley first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- Morgan Stanley's Adamas Pharmaceuticals position peaked at $6.92M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Morgan Stanley's 13F filing for Q4 2021, filed 14 Feb 2022.